Ono Pharmaceutical's R&D Day boosts pipeline confidence, but J.P. Morgan maintains Underweight

Overview

J.P. Morgan interpreted Ono Pharmaceutical's R&D Day held on June 8 and the subsequent Q&A. The report focuses on ONO-4578's opportunities in gastric cancer and colorectal cancer, ONO-2808's development path in multiple system atrophy MSA-P, and the company's drug discovery capabilities in the central nervous system field. The analysts formed a positive impression of the pipeline assets and the company's attitude toward advancing development, but the stock rating remains Underweight.

Core views

In the short term, market attention may still focus on Opdivo sales in Japan and indication expansion, but in the medium to long term the focus will gradually shift to whether there is a sufficient pipeline to carry the company into the post-Opdivo era. If ONO-4578 can sustain its response-rate advantage in PD-L1 CPS-positive and CLDN18.2 double-positive gastric cancer populations, it may open up market opportunities; if ONO-2808 can reproduce its early efficacy in Phase III for MSA-P, it will also enhance the value of the CNS pipeline. However, incomplete subgroup disclosure, clinical reproducibility, changes in the competitive landscape, and long-term profit decline remain the main uncertainties.

Analysis framework

The report mainly analyzes the company based on disclosures from the R&D Day, management Q&A, interpretation of clinical endpoints, peer comparisons, and the DCF valuation framework. On the clinical side it focuses on PFS, OS, ORR, MRI brain atrophy, UMSARS, and safety signals; on the investment side it focuses on dependence on Opdivo, follow-on pipeline succession capability, FY2027-36 earnings forecasts, and valuation multiples.

Methodology notes

• Valuation methodDCF

  Discounted cash flow

  The target price of ￥1,800 comes from a DCF model based on FY2027-36 forecasts, assuming a terminal growth rate of 0% and WACC of 7.0%.

• Clinical data interpretationPFS/OS, ORR and UMSARS

  Efficacy endpoints and disease progression assessment

  The report uses PFS, OS, and ORR to assess the antitumor efficacy of ONO-4578, and MRI brain atrophy and UMSARS to assess ONO-2808's suppression of disease progression in MSA-P.

• Rating frameworkJ.P. Morgan Equity Rating

  Underweight corresponds to the sell rating category

  In J.P. Morgan's FINRA rating distribution disclosure, Underweight falls into the sell rating category; this report's target price is significantly below the current price.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Ono Pharmaceutical (4528.T)

  The stock under coverage, a Japan-listed pharmaceutical company.

  Strengths

  It has the base Opdivo business and multiple follow-on pipelines, and the R&D Day showed the company continues to invest in oncology and the central nervous system fields.

  Weaknesses

  The core long-term issue is reducing dependence on Opdivo, and the report forecasts negative operating profit CAGR for FY2027-36.

  Comparison

  Within Japanese pharma coverage, it is covered alongside Astellas Pharma, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Takeda Pharmaceutical, and others.

  Risks

  If Opdivo sales in Japan weaken due to changes in the competitive environment, or if the follow-on pipeline fails to deliver, the rating and target price will come under pressure.

• ONO-4578

  An oncology pipeline asset related to gastric cancer and colorectal cancer, and one of the key assets highlighted at the R&D Day.

  Strengths

  It showed reduced PFS/OS risk and improved response rate in PD-L1 CPS-positive gastric cancer, and the company plans to start Phase III before year-end.

  Weaknesses

  The HR in the PD-L1 CPS-negative group was above 1, and details and interaction effects for CLDN18.2-positive subgroups were not disclosed, so some results need to be interpreted cautiously.

  Comparison

  The report compares it with anti-PD-1 antibody plus chemotherapy, zolbetuximab, and the current standard treatment of Opdivo plus chemotherapy.

  Risks

  Phase III design, treatment sequencing, progress of competing drugs, and management of gastrointestinal adverse reactions could all affect the commercialization opportunity.

• ONO-2808

  A central nervous system pipeline related to multiple system atrophy MSA-P/MSA-C.

  Strengths

  In MSA-P, MRI brain atrophy suppression and UMSARS data supported each other, with 64%-70% suppression of disease progression versus placebo at week 24.

  Weaknesses

  The company did not disclose specific methods to improve Phase III reproducibility, nor did it disclose baseline UMSARS details for ONO-2808.

  Comparison

  The report compares it with Lundbeck's amlenetug, but notes that differences in UMSARS scale items and patient characteristics make direct comparison difficult.

  Risks

  Phase III reproducibility, differences in disease progression between MSA-P and MSA-C, dose response, and safety management are key uncertainties.

• Opdivo

  The company's existing core product and the market's main focus.

  Strengths

  In the short term, it is still supported by indication expansion in Japan and its position in existing standard treatments.

  Weaknesses

  Long-term dependence remains high, and the ability of the post-Opdivo pipeline to take over has become the main investment question.

  Comparison

  In the discussion of gastric cancer treatment, Opdivo plus chemotherapy is viewed as one of the current standard treatments.

  Risks

  If sales in Japan weaken because of changes in the competitive environment, it would create a downside scenario for the rating and target price.

Key data

• Current price￥2,248Price date is 2026-06-08.
• Target price￥1,800Target price point is end-December 2026.
• Implied upside/downside-19.9%Calculated based on target price ￥1,800 and current price ￥2,248.
• ONO-4578 gastric cancer efficacy signalPFS/OS risk down 48%/56%, response rate up 20%The company said it has an advantage versus the control group and the anti-PD-1 antibody plus chemotherapy group, but some subgroup data were not disclosed.
• Share of double-positive patients25.7%Refers to the share of PD-L1 CPS-positive and CLDN18.2-positive double-positive patients among trial enrollment.
• Next milestones for ONO-4578Phase III launch before year-end, colorectal cancer POC data in FY2027The Phase III plan targets PD-L1 CPS-positive patients.
• ONO-2808 efficacy signalMSA-P showed 64%-70% suppression of progression versus placebo at week 24The company said MRI imaging diagnostic data matched the UMSARS data.
• ONO-2808 safetyALT/AST elevation was the main discontinuation-related adverse event, with no severe casesThe condition improved after discontinuation, and no additional safety signals were observed in the core and extension portions.
• Key DCF assumptionsTerminal growth rate 0%, WACC 7.0%Used to derive the end-December 2026 target price.
• Valuation multiplesFY2027E P/E 13.8x, FY2031E P/E 22.8xBased on FY2027 EPS of ￥131 and FY2031 EPS of ￥79.
• Operating profit forecastFY2027-31 CAGR -12.3%, FY2027-36 CAGR -22.8%Reflects the analysts' cautious expectations for the medium- to long-term earnings trend.

Impact & implications

The R&D Day has an incremental positive impact on confidence in the pipeline, especially as expectations for Phase III advancement of ONO-4578 and ONO-2808 may improve market attention to the post-Opdivo pipeline. However, because the target price is still below the current price and the report forecasts negative medium- to long-term operating profit CAGR, the investment implication is more about watching whether clinical milestones can materially change long-term growth and valuation assumptions, rather than immediately reversing the stock rating.

Risks

• Opdivo sales in Japan weaken due to changes in the competitive environment.
• ONO-4578 Phase III fails to reproduce its early PFS, OS, or ORR advantages.
• ONO-2808 fails to reproduce the week-24 disease progression suppression signal in Phase III for MSA-P.
• Insufficient disclosure of PD-L1 CPS, CLDN18.2, and other subgroup data creates uncertainty in efficacy interpretation.
• Changes in standard treatment pathways and competitor development trends may compress the commercial opportunity for new pipelines.
• If the assumption of long-term operating profit decline for FY2027-36 materializes, it will limit valuation upside.

What to watch

• Whether ONO-4578's Phase III trial in PD-L1 CPS-positive patients can start as scheduled before year-end.
• ONO-4578's FY2027 POC data in colorectal cancer.
• Whether ONO-4578 Phase III will add Opdivo plus chemotherapy as the current standard-treatment comparator.
• The Phase III design, endpoint selection, and result reproducibility of ONO-2808 in MSA-P.
• Baseline UMSARS differences between MSA-P and MSA-C patients and their impact on efficacy detection.
• Trends in Opdivo sales in Japan, indication expansion, and changes in the competitive landscape.
• Whether the company's CNS drug discovery platform can continue to produce assets that can be clinically validated.